Journal ArticleDOI
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Reads0
Chats0
About:
This article is published in Yearbook of Oncology.The article was published on 2010-01-01. It has received 850 citations till now. The article focuses on the topics: Dasatinib & Imatinib.read more
Citations
More filters
Journal ArticleDOI
A Pharmacist-Led Oral Chemotherapy Program's Impact on Chronic Myeloid Leukemia Patient Satisfaction, Adherence, and Outcomes.
TL;DR: Irrespective of POCP enrollment, patients reported clinical pharmacists play a major role in their therapy and value integration of their specialty pharmacy and medical team and patients in the non-POCP group reported lower satisfaction than those enrolled resulting from fragmented care that was likely due to external specialty pharmacies.
Journal ArticleDOI
Pemphigus foliaceous‐like reaction in a patient with chronic myeloid leukemia treated with the tyrosine kinase inhibitors nilotinib and dasatinib
TL;DR: A case of a pemphigus foliaceous (PF)-like reaction associated with the use of nilotinib and dasatinib is presented.
Journal ArticleDOI
Recent advances in the path toward the cure for chronic myeloid leukemia.
TL;DR: This report summarizes the detailed clinical data obtained in the DASISION, ENESTnd, and BELA studies and discusses high-sensitivity detection methods and future therapeutic strategies.
Journal ArticleDOI
The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells
Daniela Dörfel,Christian J. Lechner,Simone Joas,Tanja Funk,Michael Gutknecht,Julia Salih,Julian Geiger,Korbinian N. Kropp,Stefanie Maurer,Martin Müller,Hans-Georg Kopp,Helmut R. Salih,Frank Grünebach,Susanne M. Rittig +13 more
TL;DR: It is found that both tyrosine kinase inhibitors comparably and significantly impaired differentiation of monocytes to DCs as revealed by curtated downregulation of CD14 and reduced up regulation of CD1a and CD83, and that imatinib and nilotinib may differ significantly with regard to their influence on antitumor immunity.
Journal ArticleDOI
Managing inadequate responses to frontline treatment of chronic myeloid leukemia: A case-based review
TL;DR: It is imperative that patients who experience intolerance or who fail to achieve appropriate responses to TKI treatment are carefully evaluated so that appropriate treatment modifications can be made to maximize the likelihood of positive long-term outcome.
References
More filters
Journal ArticleDOI
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
Hagop M. Kantarjian,Neil P. Shah,Andreas Hochhaus,Jorge E. Cortes,Sandip Shah,Manuel Ayala,Beatriz Moiraghi,Zhixiang Shen,Jiri Mayer,Ricardo Pasquini,Hirohisa Nakamae,Françoise Huguet,Concepción Boqué,Charles Chuah,Eric Bleickardt,M. Brigid Bradley-Garelik,Chao Zhu,Ted Szatrowski,David Shapiro,Michele Baccarani +19 more
TL;DR: Since achieving complete cytogenetic response within 12 months has been associated with better long-term, progression-free survival, dasatinib may improve the long- term outcomes among patients with newly diagnosed chronic-phase CML.